C-reactive protein as an indicator of polymorbidity in patients with arterial hypertension
https://doi.org/10.18699/SSMJ20220209
Abstract
Aim of the study was to investigate the role of C-reactive protein as an indicator of multimorbidity in patients with arterial hypertension.
Material and methods. A retrospective archival study of the data of 1958 patients with arterial hypertension who were examined and treated at the clinic of the Federal Research Center for Fundamental and Translational Medicine (Novosibirsk) was carried out. 2 groups of patients were allocated depending on the concentration of C-reactive protein in the blood serum: normal and elevated (> 5 mg/l). A comparative analysis of the severity of polymorbidity, as well as clinical, laboratory and biochemical parameters in the selected groups were carried out.
Results. It has been established that patients with arterial hypertension with elevated values of C-reactive protein had higher rates of transnosological and transsystemic polymorbidity, accompanied by changes in lipid, carbohydrate and purine metabolism (a decrease in high-density lipoprotein cholesterol, an increase in the concentration of glucose and uric acid in blood serum, an increase in the index atherogenicity), as well as an increase in the content of fibrinogen in the blood serum.
Conclusions. The concentration of C-reactive protein in the blood serum can serve as a biochemical marker of polymorbidity in patients with arterial hypertension.
About the Authors
E. V. Sevostyanova
Federal Research Center for Fundamental and Translational Medicine
Russian Federation
Russian Federation
candidate of medical sciences
630117, Novosibirsk, Timakov str., 2
Yu. A. Nikolaev
Federal Research Center for Fundamental and Translational Medicine
Russian Federation
Russian Federation
doctor of medical sciences
630117, Novosibirsk, Timakov str., 2
I. M. Mitrofanov
Federal Research Center for Fundamental and Translational Medicine
Russian Federation
Russian Federation
doctor of medical sciences
630117, Novosibirsk, Timakov str., 2
V. Ya. Polyakov
Federal Research Center for Fundamental and Translational Medicine
Russian Federation
Russian Federation
doctor of medical sciences
630117, Novosibirsk, Timakov str., 2
References
1. Noh J., Kim H.C., Shin A., Yeom H., Jang S.Y., Lee J.H., Kim C., Suh I. Prevalence of comorbidity among people with hypertension: The Korea National Health and Nutrition Examination Survey 2007–2013. Korean Circ. J. 2016;46(5):672–680. doi: 10.4070/kcj.2016.46.5.672
2. Park C., Fang J., Hawkins N.A., Wang G. Comorbidity status and annual total medical expenditures in U.S. hypertensive adults. Am. J. Prev. Med. 2017;53(6S2):172–181. doi:10.1016/j.amepre.2017.07.014
3. Sum G., Salisbury C., Koh G.C., Atun R., Oldenburg B., McPake B., Vellakkal S., Lee J.T. Implications of multimorbidity patterns on health care utilization and quality of life in middle-income countries: crosssectional analysis. J. Glob. Health. 2019;9(2):020413. doi: 10.7189/jogh.09.020413
4. Ferreira G.D., Simões J.A., Senaratna C., Pati S., Timm P.F., Batista S.R., Nunes BP. Physiological markers and multimorbidity: A systematic review. J. Comorb. 2018; 8(1):2235042X18806986. doi: 10.1177/2235042X18806986
5. Danesh J., Kaptoge S., Mann A.G., Sarwar N., Wood A., Angleman S.B., Wensley F., Higgins J.P.T., Lennon L., Eiriksdottir G., … Gudnason V. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med. 2008;5(4):78. doi:10.1371/journal.pmed.0050078
6. Kaptoge S., Seshasai S.R., Gao P., Freitag D.F., Butterworth A.S., Borglykke A., Di Angelantonio E., Gudnason V., Rumley A., Lowe G.D., Jørgensen T., Danesh J. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. European Heart Journal. 2014;35(9):578–589. doi:10.1093/eurheartj/eht367
7. Oganov R.G., Drapkina O.M. Polymorbidity: specifics of co-development and concomitance of several diseases in one patient. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2016;15(4):4–9. [In Russian]. doi:10.15829/1728-8800-2016-4-4-9
8. Friedman E., Shorey C. Inflammation in multimorbidity and disability: An integrative review. Health Psychol. 2019;38(9):791–801. doi: 10.1037/hea0000749
9. Ridker P.M. A test in context: high-sensitivity C-reactive protein. J. Am. Coll. Cardiol. 2016; 67:712–723. doi: 10.1016/j.jacc.2015.11.037
10. Stepanova M., Rodriguez E., Birerdinc A., Baranova A. Age-independent rise of inflammatory scores may contribute to accelerated aging in multi-morbidity. Oncotarget. 2015;6(3):1414–1421. doi: 10.18632/oncotarget.2725
11. Schöttker B., Saum K.U., Jansen E.H., Holleczek B., Brenner H. Associations of metabolic, inflammatory and oxidative stress markers with total morbidity and multi-morbidity in a large cohort of older German adults. Age Ageing. 2016;45(1):127–135. doi: 10.1093/ageing/afv159
12. Garrafa E., Casnici N., Squazzoni F., Uberti D., Marengoni A. C-reactive protein, lipoprotein (a) and cystatin C levels increase with multimorbidity in older persons. Eur. J. Intern. Med. 2017;42:25–26. doi: 10.1016/j.ejim.2017.04.010
13. Lozhkina N.G., Kuimov A.D., Ragino Yu.I., Voevoda M.I. Inflammatory markers and acute coronary syndrome. Vestnik Novosibirskogo gosudarstvennogo universiteta. Seriya: Biologiya, klinicheskaya meditsina = Journal of the Novosibirsk State University. Series: Biology, Clinical Medicine. 2013;11(3):199–204 [In Russian].
14. Geovanini G.R., Libby P. Atherosclerosis and inflammation: overview and updates. Clin. Sci. (Lond). 2018;132(12):1243–1252. doi: 10.1042/CS20180306
15. Raggi P., Genest J., Giles J.T., Rayner K.J., Dwivedi G., Beanlands R.S., Gupta M. Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. Atherosclerosis. 2018;276:98–108. doi:10.1016/j.atherosclerosis.2018.07.014
16. Pant S., Deshmukh A., Gurumurthy G.S., Pothineni N.V., Watts T.E., Romeo F., Mehta J.L. Inflammation and atherosclerosis-revisited. J. Cardiovasc. Pharmacol. Ther. 2014;19(2):170–178. doi:10.1177/1074248413504994
17. Kido T., Tamagawa E., Bai N., Suda K., Yang H.H., Li Y., Chiang G., Yatera K., Mukae H., Sin D.D., Van Eeden S.F. Particulate matter induces translocation of IL-6 from the lung to the systemic circulation. Am. J. Respir. Cell. Mol. Biol. 2011;44(2):197–204. doi: 10.1165/rcmb.2009-0427OC
18. Hughes M.J., McGettrick H.M., Sapey E. Shared mechanisms of multimorbidity in COPD, atherosclerosis and type-2 diabetes: the neutrophil as a potential inflammatory target. Eur. Respir. Rev. 2020;29(155):190102. doi: 10.1183/16000617.0102-2019
19. Incalza M.A., D’Oria R., Natalicchio A., Perrini S., Laviola L., Giorgino F. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases. Vascul. Pharmacol. 2018;100:1–19. doi: 10.1016/j.vph.2017.05.005
20. Grandl G., Wolfrum C. Hemostasis, endothelial stress, inflammation, and the metabolic syndrome. Semin. Immunopathol. 2018;40(2):215–224. doi: 10.1007/s00281-017-0666-5
21. Efremov L.I., Komisarenko I.A. Metabolic continuum and polymorbidity in geriatrics. Eksperimental’naya i klinicheskaya gastroenterologiya = Experimental and Clinical Gastroenterology. 2014;6(106):4–7. [In Russian].
Review
For citations:
Sevostyanova E.V., Nikolaev Yu.A., Mitrofanov I.M., Polyakov V.Ya. C-reactive protein as an indicator of polymorbidity in patients with arterial hypertension. Сибирский научный медицинский журнал. 2022;42(2):58-64. (In Russ.) https://doi.org/10.18699/SSMJ20220209
Views:
1141
Email this article 